DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Zhang, Geng ^a   Schetter, Aaron ^a   He, Peijun ^a   Funamizu, Naotake ^a   Gaedcke, Jochen ^b   Ghadimi, B Michael ^b   Ried, Thomas ^a   Hassan, Raffit ^a   Yfantis, Harris G ^c   Lee, Dong H ^c   Lacy, Curtis ^a   Maitra, Anirban ^d   Hanna, Nader ^e   Alexander, H Richard ^e   Hussain, S Perwez ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDASE; DIPEPTIDASE 1; EPIDERMAL GROWTH FACTOR; GEMCITABINE; SELUMETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NUCLEAR PROTEIN; TPX2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CARCINOMA CELL; CHEMOSENSITIVITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIPEPTIDASE 1 GENE; DISEASE ACTIVITY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATIC DUCTAL ADENOCARCINOMA; PROTEIN EXPRESSION; VALIDATION STUDY; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COHORT STUDIES; DEOXYCYTIDINE; DIPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GPI-LINKED PROTEINS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MARYLAND; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84857383269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031507     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Yeh JJ, (2009) Prognostic signature for pancreatic cancer: are we close? Future Oncol 5: 313-321.
3. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, et al. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med.
4. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277.
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
6. Goggins M, (2007) Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 34: 303-310.
7. Kolbert CP, Chari S, Sreekumar R, (2008) Microarray technologies for gene transcript analysis in pancreatic cancer. Technol Cancer Res Treat 7: 55-59.
8. Grutzmann R, Boriss H, Ammerpohl O, Luttges J, Kalthoff H, et al. (2005) Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24: 5079-5088.
9. Campagna D, Cope L, Lakkur SS, Henderson C, Laheru D, et al. (2008) Gene expression profiles associated with advanced pancreatic cancer. Int J Clin Exp Pathol 1: 32-43.
10. Kim HN, Choi DW, Lee KT, Lee JK, Heo JS, et al. (2007) Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer. Pancreas 34: 325-334.
11. Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, et al. (2010) A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 7: e1000307.
12. Aaltonen LA, Hamilton SR, World Health Organization, International Agency for Research on Cancer (2000) Pathology and genetics of tumours of the digestive system Lyon Oxford IARC Press; Oxford University Press (distributor).
13. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP, (2005) Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 41: 2213-2236.
14. Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, et al. (2009) Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res 15: 6519-6528.
15. Kim MP, Gallick GE, (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14: 1284-1285.
16. Giehl K, Skripczynski B, Mansard A, Menke A, Gierschik P, (2000) Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 19: 2930-2942.
17. Lopez-Casas PP, Lopez-Fernandez LA, (2010) Gene-expression profiling in pancreatic cancer. Expert Rev Mol Diagn 10: 591-601.
18. Okamoto T, Matsumura N, Mandai M, Oura T, Yamanishi Y, et al. (2010) Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1. Mod Pathol 24: 267-276.
19. Toiyama Y, Inoue Y, Yasuda H, Saigusa S, Yokoe T, et al. (2010) DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness. J Gastroenterol 46: 153-163.
20. Green AR, Krivinskas S, Young P, Rakha EA, Paish EC, et al. (2009) Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. Breast Cancer Res Treat 113: 59-66.
21. Austruy E, Cohen-Salmon M, Antignac C, Beroud C, Henry I, et al. (1993) Isolation of kidney complementary DNAs down-expressed in Wilms' tumor by a subtractive hybridization approach. Cancer Res 53: 2888-2894.
22. McIver CM, Lloyd JM, Hewett PJ, Hardingham JE, (2004) Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett 209: 67-74.
23. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
24. Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, et al. (1997) Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19: 161-169.
25. Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, et al. (1998) The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106 (Suppl 1): 289-295.
26. Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, et al. (2009) Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs 14: 311-328.